Bulk Inquiry
Lenvatinib
- E7080
- Soluble in DMSO
- MF: C21H19ClN4O4
- MW: 426.85
Description
Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. Lenvatinib inhibited Flt-1 (VEGFR1), KDR (VEGFR2) and Flt-4 (VEGFR3) with IC50 values of 22, 4.0 and 5.2 nM, respectively. Lenvatinib has potent antitumor activity against human H146, a SCLC cell line in mice based on angiogenesis inhibition via both KDR and KIT signaling, compared to single inhibition of either KDR or KIT signaling.
More Information
| Parent CAS No. | 417716-92-8 |
|---|---|
| Chemical Name | 4-(3-Chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide |
| SMILES | C1(OC)=CC2N=CC=C(OC3C=C(Cl)C(NC(=O)NC4CC4)=CC=3)C=2C=C1C(=O)N |
| MFCD | MFCD16038644 |
| InChi | InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28) |
| InChiKey | WOSKHXYHFSIKNG-UHFFFAOYSA-N |
| CID | 9823820 |
| Short Description | RTK inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1398 | Sunitinib malate |
From $88.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1638 | ABT 869 |
From $88.00 |
| 1678 | Regorafenib |
From $77.00 |
| 1768 | AMG 706 |
From $115.50 |
| 1819 | Cabozantinib S-malate |
From $66.00 |
| 1892 | 1-NM-PP1 |
From $104.50 |
| 2219 | AT 9283 |
From $99.00 |
| 2501 | Pexidartinib |
From $66.00 |
| 2553 | LY 2801653 |
From $132.00 |
| 2767 | SU11652 |
From $154.00 |
| 3624 | Toceranib phosphate |
From $66.00 |
| 3946 | Altiratinib |
From Inquiry |
| 3969 | Crenolanib |
From Inquiry |
| 3973 | XL-228 |
From Inquiry |
| 3975 | MGCD265 dihydrochloride |
From $143.00 |
| 3998 | MGCD516 |
From Inquiry |
| 4073 | CYC-116 |
From Inquiry |
| 4388 | JNJ-42756493 |
From $88.00 |
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.